An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

NCT05245994 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Small Cell Lung Cancer
Durvalumab

Interventions

DRUG: Durvalumab, etoposide, and cisplatin/carboplatin followed by durvalumab and olaparib

Sponsor

Li Zhang, MD